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Introduction {#sec1}
============

Inflammasomes are intracellular multi-protein complexes that respond to a wide range of stimuli, including invading pathogens, host cell-derived danger signals, and environmental irritants ([@bib24]; [@bib51]). Numerous different inflammasomes exist, each responding to its own activating stimuli. The NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome is one of the best characterized inflammasomes, consisting of its central protein NLRP3, the adaptor protein ASC (also known as PYCARD), the mitotic kinase NIMA-related kinase 7 (NEK7) ([@bib11]; [@bib41]; [@bib46]), and the effector protein caspase-1. NLRP3 consists of three domains: an amino-terminal pyrin domain (PYD), a carboxy-terminal leucine-rich repeat (LRR) domain, and a central NACHT domain ([@bib18]). Interactions between NLRP3 and NEK7 are essential for NLRP3 oligomerization and associated inflammasome activation, and these occur at multiple surfaces in the LRR and NACHT domains of NLRP3 ([@bib42]). Activation of the NLRP3 inflammasome results in caspase-1-mediated cleavage of pro-IL-1β, pro-IL-18, and gasdermin D into their active subunits. Despite advances in our understanding of the interactions that facilitate NLRP3 activation, a unifying molecular pathway from stimulus to NLRP3 activation remains to be elucidated. This is further complicated by the fact that the stimuli that trigger NLRP3 activation are so wide-ranging: potassium efflux ([@bib34]), chloride efflux ([@bib5]; [@bib52]), lysosomal disruption ([@bib17]), *trans*-Golgi network disassembly ([@bib1]), and mitochondrial dysfunction ([@bib9]; [@bib47]) are notable NLRP3-activating stimuli. The NLRP3 inflammasome may also be regulated metabolically. Mitochondrial localization of NLRP3 is thought to precede inflammasome activation ([@bib20]), and mitochondrial reactive oxygen species (ROS) have been implicated in NLRP3 activation ([@bib9]). Furthermore, the ketone body β-hydroxybutyrate, produced as a result of a metabolic shift to fatty acid oxidation in conditions of low glucose, is an endogenous inhibitor of NLRP3 activation ([@bib55]).

NLRP3 has been implicated in several diseases. Cryopyrin-associated periodic syndrome (CAPS) refers to a group of autoinflammatory disorders characterized by autosomal dominant mutations in *Nlrp3*, resulting in dysregulated release of IL-1β ([@bib15]) and the development of multi-organ systemic inflammation. The role of NLRP3 in disease is not restricted to monogenic NLRP3-driven diseases, however, as NLRP3 has been implicated in a wide range of different autoinflammatory diseases including Alzheimer disease and rheumatoid arthritis ([@bib29]). The pathological involvement of NLRP3 therefore necessitates that its activation is tightly regulated. A major mechanism involves post-translational modifications. NLRP3 is ubiquitylated under resting conditions ([@bib22]), whereas its phosphorylation and acetylation promote activation ([@bib13]; [@bib49]). Covalent inhibitors of NLRP3, which include parthenolide ([@bib21]) and oridonin ([@bib12]), have revealed that NLRP3 is also susceptible to electrophilic modification of reactive cysteines, thus opening up another potential route through which NLRP3 inflammasome activation may be controlled.

Itaconate is an unsaturated dicarboxylic acid that is synthesized from the decarboxylation of the Krebs cycle intermediate *cis*-aconitate by the enzyme immune-responsive gene 1 (IRG1), also termed ACOD1 ([@bib16]; [@bib32]; [@bib35]). Itaconate is a prime example of metabolic reprogramming in macrophages. Although synthesized as a by-product of the Krebs cycle, its production is scaled up upon LPS treatment ([@bib26]) seemingly with the purpose of restraining macrophage immune responses to TLR stimulation. Endogenous itaconate and/or its cell-permeable derivative 4-octyl itaconate (4-OI) have been shown to alkylate cysteine residues on multiple proteins, including kelch-like ECH-associated protein 1 (KEAP1) ([@bib33]), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) ([@bib27]), aldolase A (ALDOA) ([@bib37]), and receptor-interacting serine/threonine-protein kinase 3 (RIPK3) ([@bib38]). This form of cysteine alkylation, termed 2,3-dicarboxypropylation or itaconation, has been shown to be an important part of the anti-inflammatory properties of itaconate. As an example, the modification of KEAP1 activates the antioxidant transcription factor nuclear factor erythroid 2-related factor 2 (NRF2), thereby blocking macrophage IL-1β transcription following LPS stimulation, which requires ROS ([@bib33]). However, the effect of itaconate on inflammasome-dependent IL-1β cleavage and release has not been fully explored. Here we provide evidence that itaconate modifies a specific cysteine (C548) on NLRP3 and inhibits NLRP3 activation by interfering with the interaction between NLRP3 and NEK7. Itaconate may therefore be an important negative regulator of NLRP3, which could have utility as a therapy in NLRP3-mediated diseases.

Results {#sec2}
=======

4-OI Specifically Blocks NLRP3 Inflammasome Activation {#sec2.1}
------------------------------------------------------

Treatment of LPS-primed bone marrow-derived macrophages (BMDMs) with 4-OI prior to activation of NLRP3 with ATP or nigericin ([Figure 1](#fig1){ref-type="fig"} A) resulted in a concentration-dependent reduction in IL-1β release ([Figures 1](#fig1){ref-type="fig"}B and 1D) as well as a reduction in LDH release ([Figures 1](#fig1){ref-type="fig"}C and 1E), which is used as a measure of pyroptosis. Cleavage and release of IL-1β in this assay were NLRP3-dependent ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). The effect of 4-OI was confirmed by western blot as it blocked the cleavage of IL-1β and caspase-1 to their mature p17 and p20 forms, respectively ([Figures 1](#fig1){ref-type="fig"}F and 1G, compare lanes 5--7 to lane 4). 4-OI also blocked the cleavage of gasdermin D, the pyroptosis executioner ([@bib44]), to its active N-terminal fragment ([Figure S1](#mmc1){ref-type="supplementary-material"}C, compare lanes 5--7 to lane 4). Dimethyl itaconate (DMI), a different itaconate derivative, similarly blocked IL-1β release and cleavage ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E). However, the octyl control compounds 4-octyl succinate (4-OS) and 4-octyl-2-methyl succinate (4-O-2-MS), designed to control for the potentially reactive octyl tail on 4-OI, did not block IL-1β cleavage and release to the same extent ([Figures S1](#mmc1){ref-type="supplementary-material"}F--S1H). The specific NLRP3 inhibitor MCC950 ([@bib2]) was also used as a control in these experiments ([Figures S1](#mmc1){ref-type="supplementary-material"}I and S1J). The cytokine IL-18 is co-secreted with IL-1β in an NLRP3-dependent manner ([@bib8]), and its release was completely inhibited by 4-OI ([Figure 1](#fig1){ref-type="fig"}H). Upon NLRP3 inflammasome activation, the adaptor protein ASC is recruited by NLRP3 and forms large multimeric complexes ([@bib28]), termed ASC specks. We found that 4-OI inhibited ASC speck formation, as detected by flow cytometry ([Figure 1](#fig1){ref-type="fig"}I), and reduced the appearance of large multimeric ASC complexes, as detected by western blot ([Figure 1](#fig1){ref-type="fig"}J, compare lane 4 to lane 3).Figure 14-OI Blocks NLRP3 Inflammasome Activation(A) Time flow of NLRP3 inflammasome assay with 4-OI in BMDMs.(B and C) LPS (3 h) and ATP (45 min) induced IL-1β release (B, n = 10) and LDH release (C, n = 4 for ATP alone, n = 7 for others, measured as % LDH release of total lysis control) ± 4-OI.(D and E) LPS (3 h) and nigericin (45 min) induced IL-1β release (D, n = 7) and LDH release (E, n = 5 for NS alone, n = 6 for others) ± 4-OI.(F and G) Immunoblot analysis (F) and quantification by densitometry (G, n = 4) of pro- and mature caspase-1 and IL-1β protein in lysates and supernatants of BMDMs treated with LPS (3 h) and nigericin (45 min) ± 4-OI.(H) LPS (3 h) and nigericin (45 min) induced IL-18 release ± 4-OI (n = 5).(I) Percent of all cells positive for ASC specks in LPS- (3 h) and nigericin- (45 min) treated BMDMs ± 4-OI (n = 6).(J) Immunoblot analysis of ASC protein in triton-insoluble pellet and -soluble lysate of LPS- (3 h) and nigericin- (45 min) treated BMDMs ± 4-OI (250 μM).^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. Data are mean ± SEM. Blots are representative of a minimum of 3 independent experiments.

It was important to ensure that any effect was specific to NLRP3 activation rather than priming. We found that 4-OI did not affect tumor necrosis factor α (TNFα) release ([Figure S2](#mmc1){ref-type="supplementary-material"}A) and only inhibited pro-IL-1β expression when added before LPS priming and not after LPS priming ([Figure S2](#mmc1){ref-type="supplementary-material"}B, compare lanes 3--5 to lane 2 and lanes 7--9 to lane 6), in accordance with previous findings ([@bib33]). In order to elucidate whether the effect was specific to the NLRP3 inflammasome, we also tested 4-OI in AIM2, NLRC4, and non-canonical inflammasome assays. 4-OI, when added between LPS and poly(dA:dT) transfection, did not reduce IL-1β release or pyroptosis associated with AIM2 inflammasome activation ([Figures 2](#fig2){ref-type="fig"}A and 2B). Furthermore, it had no effect on IL-1β or caspase-1 cleavage ([Figures 2](#fig2){ref-type="fig"}C and 2D, compare lanes 5 and 6 to lane 4). We made similar observations when 4-OI was added to cells between LPS and transfection of purified flagellin to activate the NLRC4 inflammasome. IL-1β release, pyroptosis, and cleavage of IL-1β and caspase-1 were unaffected by addition of 4-OI ([Figures 2](#fig2){ref-type="fig"}E--2H). The non-canonical inflammasome differs from canonical inflammasome signaling in that it senses cytosolic LPS using the effector protein caspase-11 (caspase-4 and -5 in humans) ([@bib23]; [@bib43]). Although pyroptosis in this model is caspase-11 dependent, IL-1β release remains dependent on canonical NLRP3 activation, as this occurs secondary to K^+^ efflux resulting from pyroptosis ([@bib39]). We added 4-OI in between LPS priming and LPS transfection in a non-canonical inflammasome assay and found that it blocked IL-1β release, but not pyroptosis, in this assay, further indicating the specific targeting of NLRP3 ([Figures 2](#fig2){ref-type="fig"}I and 2J).Figure 24-OI Does Not Block Activation of Other Inflammasomes(A and B) LPS (3 h) and poly(dA:dT) (6 h) induced IL-1β release (A, n = 5) and LDH release (B, n = 5) ± 4-OI.(C and D) Immunoblot analysis (C) and quantification by densitometry (D, n = 3) of pro- and mature caspase-1 and IL-1β protein in lysates and supernatants of BMDMs treated with LPS (3 h) and poly(dA:dT) (6 h) ± 4-OI.(E and F) LPS (3 h) and flagellin (2.5 h) induced IL-1β release (E, n = 8) and LDH release (F, n = 5) ± 4-OI.(G and H) Immunoblot analysis (G) and quantification by densitometry (H, n = 3) of pro- and mature caspase-1 and IL-1β protein in lysates and supernatants of BMDMs treated with LPS (3 h) and flagellin (2.5 h) ± 4-OI.(I and J) LPS priming (3 h) and transfection (18 h) induced IL-1β release (I, n = 5) and LDH release (J, n = 5) ± 4-OI.^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. Data are mean ± SEM. Blots are representative of a minimum of 3 independent experiments.

Endogenous Itaconate Regulates NLRP3 Inflammasome Activation {#sec2.2}
------------------------------------------------------------

Although 4-OI treatment boosts levels of unmodified itaconate in activated macrophages ([@bib33]), it is unclear whether LPS stimulation is required for this increase and whether the intracellular itaconate arises from de-esterification of 4-OI or from increased production of endogenous itaconate ([@bib50]). We therefore examined whether 4-OI could directly generate itaconate. As shown in [Figure S2](#mmc1){ref-type="supplementary-material"}C, ^13^C~5~-labeled itaconate was detected in human macrophages treated with ^13^C~5~ octyl itaconate both in the presence and absence of LPS. ^13^C~5~ itaconate was detectable as soon as 30 min after treatment with ^13^C~5~ octyl itaconate. This confirmed that 4-OI can indeed generate itaconate directly.

It is also unclear as to whether a transporter or cell-surface receptor exists for exogenous itaconate, hence the widespread use of itaconate derivatives in the field of itaconate biology. However, isotope tracing studies have shown that itaconate does accumulate in macrophages exposed to high concentrations of itaconic acid in culture media ([@bib36]; [@bib50]). Pre-treatment of BMDMs with itaconic acid (pH 7) prior to LPS and nigericin stimulation resulted in a significant and concentration-dependent reduction in IL-1β release ([Figure S2](#mmc1){ref-type="supplementary-material"}E) and a non-significant reduction in pyroptosis ([Figure S2](#mmc1){ref-type="supplementary-material"}F). Thus, unmodified itaconate, as well as derivatized itaconate, is capable of regulating NLRP3 activation.

The enzyme IRG1 is responsible for the production of itaconate in macrophages, which reaches a concentration of 5 mM in LPS-stimulated BMDMs ([@bib33]). It is therefore possible to deplete or induce the production of endogenous itaconate through manipulation of IRG1. We performed NLRP3 inflammasome assays in *Irg1* ^−/−^ BMDMs and found that IL-1β release was significantly increased relative to wild-type (WT) BMDMs ([Figure 3](#fig3){ref-type="fig"} A). There was also a non-significant increase in pyroptosis in *Irg1* ^−/−^ BMDMs ([Figure 3](#fig3){ref-type="fig"}B). IL-1β and caspase-1 processing into their mature forms, as detected by western blot, was increased in *Irg1* ^−/−^ BMDMs ([Figures 3](#fig3){ref-type="fig"}C and 3D, compare lane 8 to lane 4). These effects were specific for NLRP3 inflammasome activation, as IL-1β release resulting from AIM2 inflammasome activation was not increased in *Irg1* ^−/−^ BMDMs ([Figure S2](#mmc1){ref-type="supplementary-material"}G). As NLRP3 expression is LPS-inducible as part of priming, we verified that increased NLRP3 inflammasome activation in *Irg1* ^−/−^ BMDMs was not due to increased NLRP3 expression ([Figure S2](#mmc1){ref-type="supplementary-material"}H, compare lane 4 to lane 2).Figure 3Endogenous Itaconate Regulates NLRP3 Activation and 4-OI Dicarboxypropylates C548 on NLRP3(A and B) LPS (3 h) and nigericin (45 min) induced IL-1β release (A, n = 6) and LDH release (B) in wild-type (WT, n = 7) and *Irg1*^−/−^ (n = 8) BMDMs.(C and D) Immunoblot analysis (C) and quantification by densitometry (D, n = 4) of pro- and mature caspase-1 and IL-1β protein in lysates and supernatants of wild-type (WT) and *Irg1*^−/−^ BMDMs treated with LPS (3 h) and nigericin (45 min).(E) IL-1β release from NLRP3 inflammasome-reconstituted HEK293T cells treated with nigericin (45 min) (n = 3). Immunoblot analysis of pro- and mature IL-1β and IRG1 protein in supernatants and lysates of these cells.(F) Endogenous co-immunoprecipitation of NLRP3 and NEK7 in BMDMs treated with LPS (3 h) and nigericin (45 min) ± 4-OI (250 μM).(G) Tandem mass spectrometry spectrum of C548-containing NLRP3 peptide following 4-OI treatment (250 μM, 24 h).^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. Data are mean ± SEM. Blots are representative of a minimum of 3 independent experiments.

It is possible to reconstitute the murine NLRP3 inflammasome in HEK293T cells, as previously described ([@bib45]). Transfection of the various NLRP3 inflammasome components followed by stimulation with nigericin results in IL-1β cleavage and release from the cell ([Figure 3](#fig3){ref-type="fig"}E). We found that overexpression of a plasmid encoding IRG1 in this system resulted in reduced IL-1β cleavage and release relative to transfection of an empty vector plasmid ([Figure 3](#fig3){ref-type="fig"}E, compare lane 4 to lane 3). Thus, while the absence of endogenous itaconate boosts NLRP3 inflammasome activation, increased IRG1 expression has the opposite effect, indicating that endogenous itaconate regulates NLRP3.

4-OI Blocks the NLRP3-NEK7 Interaction and Dicarboxypropylates C548 on NLRP3 {#sec2.3}
----------------------------------------------------------------------------

Itaconate alkylates C151 on KEAP1, in a modification termed 2,3-dicarboxypropylation ([@bib33]), leading to activation of NRF2, a protein that is thought to regulate NLRP3 inflammasome activation ([@bib7]; [@bib56]). However, we found that 4-OI still inhibited NLRP3-dependent caspase-1 and IL-1β processing, as well as IL-1β release in *Nfe2l2* ^−/−^ (gene encoding NRF2) BMDMs ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3D), ruling out NRF2 in the inhibitory process. Itaconate also limits inflammation through inhibition of succinate dehydrogenase (SDH) ([@bib3]; [@bib25]). The SDH inhibitor dimethyl malonate (DMM), however, did not inhibit IL-1β release in an NLRP3 inflammasome assay ([Figure S3](#mmc1){ref-type="supplementary-material"}E), indicating that SDH inhibition was unlikely to be important here. We also explored whether 4-OI may be interacting with the deglutathionylating enzyme glutathione transferase omega 1 (GSTO1-1), recently described as a regulator of NLRP3 inflammasome activation ([@bib19]). However, 4-OI still inhibited IL-1β release in an NLRP3 inflammasome assay in *Gsto1* ^−/−^ BMDMs ([Figures S3](#mmc1){ref-type="supplementary-material"}F and S3G).

We subsequently hypothesized that the acute and specific effect of 4-OI on NLRP3 activation may be the result of targeting NLRP3 and/or NEK7 directly, but not ASC or caspase-1 as these components are shared by other inflammasomes. Upon NLRP3 inflammasome stimulation, NLRP3 and NEK7 interact with each other to promote activation ([@bib42]). This interaction was blocked by treatment with 4-OI ([Figure 3](#fig3){ref-type="fig"}F, compare lane 3 to lane 2). Subsequent tandem mass spectrometry of murine NLRP3, immunoprecipitated from 4-OI-treated NLRP3-overexpressing HEK293T cells, showed that 4-OI dicarboxypropylated (+242.15 Da) C548 on NLRP3 ([Figure 3](#fig3){ref-type="fig"}G). C548 is present in the helical domain 2 (HD2) of NLRP3, which is one of the surfaces at which NLRP3 interacts with NEK7 ([@bib42]). This points to a possible mechanism for inhibition of NLRP3, involving modification of NLRP3 on C548. This might interfere with the interaction between NLRP3 and NEK7, thereby blocking NLRP3 inflammasome activation.

4-OI Reduces NLRP3-Driven Peritonitis *In Vivo* and Blocks IL-1β Release from Human CAPS PBMCs {#sec2.4}
----------------------------------------------------------------------------------------------

Monosodium urate (MSU) crystals, the causative agent of gout, are activators of the NLRP3 inflammasome and cause caspase-1- and ASC-dependent inflammation when injected into mice intraperitoneally ([@bib30]). Co-injection of 4-OI with MSU crystals reduced IL-1β and IL-6 (which is downstream of IL-1β) concentrations, as well as neutrophil numbers, in the peritoneal lavage fluid ([Figures 4](#fig4){ref-type="fig"}A--4C).Figure 44-OI Reduces Inflammation in a Murine *In Vivo* Model of Peritonitis and Blocks NLRP3 Inflammasome Activation in Healthy Human and CAPS PBMCs(A--C) IL-1β concentration (A), IL-6 concentration (B), and neutrophil number (C) in the peritoneal lavage fluid of mice injected for 6 h with MSU crystals (30 mg/kg) ± 4-OI (50 mg/kg) (n = 3 for PBS groups, n = 8 for MSU groups).(D) LPS or Pam3CSK4 (14 h) and nigericin (2 h) induced IL-1β release (n = 5 for LPS + nigericin, n = 3 for Pam3CSK4 + nigericin) ± 4-OI or 4-O-2-MS (both 250 μM) from healthy human PBMCs.(E and F) Immunoblot analysis (E) and quantification by densitometry (F, n = 3) of pro- and mature IL-1β protein in lysates and supernatants of human PBMCs treated with LPS (14 h) and nigericin (2 h) ± 4-OI (250 μM).(G) LPS (1 h) induced IL-1β release (n = 3) ± 4-OI (250 μM) or MCC950 (500 nM) from PBMCs isolated from CAPS patients.^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. Data are mean ± SEM. Blots are representative of a minimum of 3 independent experiments.

Finally, we tested 4-OI on peripheral blood mononuclear cells (PBMCs) from CAPS patients. We first confirmed that 4-OI would block NLRP3 activation in human PBMCs isolated from healthy donors. 4-OI, but not 4-O-2-MS, blocked IL-1β release when added between Pam3CSK4 or LPS and nigericin in human PBMCs ([Figure 4](#fig4){ref-type="fig"}D). 4-OI also blocked IL-1β cleavage into its mature form ([Figures 4](#fig4){ref-type="fig"}E and 4F, compare lane 5 to lane 4). The efficacy of 4-OI was similar to that of MCC950 and glyburide, albeit at a higher concentration ([Figure S4](#mmc1){ref-type="supplementary-material"}A). PBMCs can also engage an "alternative" inflammasome pathway, which involves caspase-8 and NLRP3, and can be activated by LPS alone ([@bib6]). 4-OI blocked IL-1β release from human PBMCs in this assay ([Figure S4](#mmc1){ref-type="supplementary-material"}B). We then tested PBMCs isolated from the whole blood of CAPS patients who have hyperactive NLRP3, which can be stimulated with LPS to release large amounts of IL-1β. We treated CAPS PBMCs with 4-OI after 1 h stimulation with LPS and found that both 4-OI and MCC950 blocked IL-1β release from these cells ([Figure 4](#fig4){ref-type="fig"}G).

Discussion {#sec3}
==========

It is now generally accepted that NLRP3 inflammasome signaling plays a critical role in the pathogenesis of several autoimmune disorders, including Alzheimer disease ([@bib14]), rheumatoid arthritis ([@bib54]), and type 2 diabetes ([@bib31]; [@bib53]). This has heightened the need for a greater understanding of how inflammasome activation is regulated endogenously and how it may be inhibited.

We hereby provide evidence of itaconate being a specific endogenous inhibitor of NLRP3 inflammasome activation. Previous studies have pointed toward a role for itaconate in regulating IL-1β cleavage ([@bib25]; [@bib50]), but by pre-treating cells with itaconate prior to LPS stimulation they were unable to rule out an effect on signal 1. Nor did these studies demonstrate itaconate's specificity for NLRP3, which we have shown through our AIM2 and NLRC4 experiments.

The mechanism that we propose for this inhibition is itaconate-mediated dicarboxypropylation of C548. This particular modification was also detected by Qin et al. using an itaconate-alkyne (iTALK) probe in Raw264.7 macrophages ([@bib38]). It is possible that modification of NLRP3 at this surface would abolish its ability to interact with NEK7, a process that is necessary for inflammasome activation to take place ([@bib42]). However, further studies are required to establish (1) whether endogenous itaconate, as well as 4-OI, can cause the same modification---the study by Qin et al. indicates that this might be the case ([@bib38]); (2) whether modification at this surface is functionally relevant with regard to inflammasome activation; and (3) whether there may be other targets for dicarboxypropylation along this pathway. Qin et al. also detected "itaconation sites" on gasdermin D, the pyroptosis executioner ([@bib38]), further emphasizing the inhibitory effect of itaconate on pyroptosis. In addition, the recent observation that NEK7 deglutathionylation of C253 promotes NLRP3 inflammasome activation ([@bib19]) demonstrates that post-transcriptional modifications of NEK7 are also important in regulating inflammasome function.

Our observation that unmodified itaconic acid can limit NLRP3 activation is important when comparing the compounds widely used to deliver itaconate intracellularly. There has been a focus on how unmodified and derivatized itaconate diverge in their ability to accumulate inside the cell and exert immunomodulatory functions ([@bib50]). However, we demonstrated that ^13^C~5~-labeled octyl itaconate was converted into ^13^C~5~ itaconate intracellularly and also found consistency in the way 4-OI and itaconic acid inhibited NLRP3 inflammasome activation. In contrast to the view of [@bib50], we feel that 4-OI can be used as a tool compound in the study of itaconate, since we have shown that it can be taken up and converted to intracellular itaconate by macrophages. We have previously also demonstrated that there is significant overlap in the cysteine residues alkylated by 4-OI and endogenous itaconate ([@bib33]). In spite of this, it must be acknowledged that the relative electrophilicity of 4-OI/DMI, and therefore its ability to impact certain pathways (such as the ATF3-IKBζ axis), is higher than that of unmodified itaconate ([@bib50]). As such, any results obtained with these derivatives must be verified in *Irg1* ^−/−^ experiments in order to be considered attributable to itaconate.

Our studies performed in *Irg1* ^−/−^ macrophages have shown that an absence of endogenous itaconate results in dysregulated IL-1β release and increased pyroptosis, establishing the importance of the itaconate-NLRP3 axis in restraining macrophage inflammation. Evidence suggests that, at least in the context of NLRP3 inflammasome activation, the presence of itaconate would limit pathogenic inflammation and resulting damage to the host. Recent studies showed that plasma itaconate levels correlated with improved disease score and reduced severity in patients with rheumatoid arthritis ([@bib4]) and COVID-19 ([@bib48]), respectively. These studies add further weight to the concept that itaconate is a critical determinant of innate immune responses, with profound anti-inflammatory effects.

In conclusion, our work provides evidence for the regulation of NLRP3 by itaconate. Furthermore, in 4-OI we present a compound that may be developed further for the treatment of NLRP3-driven disorders, as evidenced by its effect on IL-1β release from CAPS PBMCs. The targeting of NLRP3 by itaconate therefore holds tremendous therapeutic potential and expands the role of itaconate as a key immunometabolite that regulates innate immunity and inflammation.

Limitations of Study {#sec3.1}
--------------------

Our study has demonstrated that 4-OI modifies C548 of NLRP3, a mechanism that is likely to be responsible for itaconate-mediated inhibition of inflammasome activation. However, further studies are required to demonstrate the functional effects of this modification, perhaps through site-directed mutagenesis of C548. Furthermore, the identification by Qin et al. of two additional cysteines undergoing modification, C284 and C720 ([@bib38]), should also be functionally investigated. Qin et al. also uncovered modification of gasdermin D on C77 and C192 ([@bib38]), which coupled with our results showing reduced gasdermin D cleavage with 4-OI, means that the effect of itaconate on gasdermin D should be examined. These studies should further emphasize the importance of the targeting of NLRP3-mediated pyroptosis as a key aspect of the anti-inflammatory effects of itaconate.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-β-actinSigmaCat\# A5316; RRID: [AB_476743](nif-antibody:AB_476743){#interref40}Anti-ASCSanta CruzCat\# Sc-22514-r; RRID: [AB_2174874](nif-antibody:AB_2174874){#interref45}Anti-Caspase-1AdipogenCat\# AG-20B-0042-C100; RRID: [AB_2755041](nif-antibody:AB_2755041){#interref50}Anti-CD11b eFluor 660InvitrogenCat\# 50-0112-82; RRID: [AB_11218507](nif-antibody:AB_11218507){#interref55}Anti-CD16/CD32BiolegendCat\# 101302; RRID: AB_312801Anti-CD45 APC/Cy7BiolegendCat\# 103116; RRID: AB_312981Anti-FLAGSigmaCat\# F1804; RRID: [AB_262044](nif-antibody:AB_262044){#interref60}Anti-GSDMDSigmaCat\# G7422; RRID: [AB_1850381](nif-antibody:AB_1850381){#interref65}Anti-GSTO1-1GenetexCat\# GTX118439; RRID: [AB_11174551](nif-antibody:AB_11174551){#interref70}Anti-HASigmaCat\# H3663; RRID: [AB_262051](nif-antibody:AB_262051){#interref75}Anti-IL-1βR&DCat\# AF-401-NA; RRID: [AB_416684](nif-antibody:AB_416684){#interref80}Anti-IL-1β (Human)R&DCat\# AF-201-NA; RRID: [AB_354387](nif-antibody:AB_354387){#interref85}Anti-IRG1AbcamCat\# AB222411Anti-Ly6GBiolegendCat\# 127611; RRID: [AB_1877212](nif-antibody:AB_1877212){#interref90}Anti-NEK7AbcamCat\# AB133514Anti-NLRP3Cell SignalingCat\# D4D8T; RRID: [AB_2722591](nif-antibody:AB_2722591){#interref95}Anti-NRF2Cell SignalingCat\# 12721S; RRID: [AB_2715528](nif-antibody:AB_2715528){#interref100}Anti-Rabbit IgG Alexa Fluor 488InvitrogenCat\# A-11008; RRID: [AB_143165](nif-antibody:AB_143165){#interref105}Rabbit IgGMerckCat\# PP64; RRID: AB_97852**Chemicals, Peptides, and Recombinant Proteins**4-Octyl ItaconateProfessor Richard Hartley, University of GlasgowCat\# N/A4-Octyl SuccinateProfessor Richard Hartley, University of GlasgowCat\# N/A4-Octyl-2-Methyl SuccinateProfessor Richard Hartley, University of GlasgowCat\# N/AA/G PLUS Agarose BeadsSanta CruzCat\# sc-2003ATPInvivogenCat\# tlrl-atplCoomassie Blue R-250CaymanCat\# 14500Disuccinimidyl SuberateThermoFisherCat\# 21655ElastasePromegaCat\# V1891FuGENE HD Transfection ReagentPromegaCat\# E2311Itaconic AcidSigmaCat\# I29204Lipofectamine 2000ThermoFisherCat\# 11668030LPS from *E.coli* O127:B8SigmaCat\# L5668LymphoprepStemCell Technologies, Inc.Cat\# 07861Monosodium Urate CrystalsInvivogenCat\# tlrl-msuNigericinInvivogenCat\# tlrl-nigPam3SCK4InvivogenCat\# tlrl-pmsPoly (dA:dT)InvivogenCat\# tlrl-patnPurified Flagellin from *P.aeruginosa*InvivogenCat\# tlrl-paflaRecombinant Human M-CSFPeprotechCat\# 300-25Strataclean ResinAgilent TechnologiesCat\# 400714Ultrapure rough LPS from *E. coli*, serotype EH100EnzoCat\# ALX-581-010-L001Zombie Green Fixable Viability KitBiolegendCat\# 423111**Critical Commercial Assays**Cytotox 96 non-radioactive cytotoxicity assayPromegaCat\# G1780Human IL-1β DuoSet ELISAR&D SystemsCat\# DY201Mouse IL-1β DuoSet ELISAR&D SystemsCat\# DY401Mouse IL-1β Quantikine ELISAR&D SystemsCat\# MLB00CMouse IL-18 ELISAInvitrogenCat\# BMS618-3Mouse IL-6 DuoSet ELISAR&D SystemsCat\# DY406Mouse TNFα DuoSet ELISAR&D SystemsCat\# DY410**Experimental Models: Cell Lines**Human: HEK293T cellsSigmaCat\# 12022001**Experimental Models: Organisms/Strains**Mouse: C57BL/6HarlanN/AMouse: C57BL/6N-Acod1^em1(IMPC)J^/JJacksonCat\# 029340Mouse: GSTO1-1^−/−^ 129/SvEv-C57BL/6TaconicCat\# TF1210**Recombinant DNA**FLAG-NLRP3[@bib46]Addgene; Cat\# 75127FLAG-Pro-Caspase-1[@bib46]Addgene; Cat\# 75128FLAG-pro-IL-1β[@bib46]Addgene; Cat\# 75131GFP-IRG1OrigeneCat\# MG217265HA-ASC[@bib57]Addgene; Cat\# 41553HA-NEK7[@bib46]Addgene; Cat\# 75142**Software and Algorithms**FlowJo v 10.7FlowJo<https://www.flowjo.com/solutions/flowjo>Graphpad Prism 8.0Graphpad<https://www.graphpad.com/>Image Lab 6.1Bio-Rad<https://www.bio-rad.com>PEAKS Studio 8Bioinformatics Solutions<https://www.bioinfor.com/peaks-studio/>

Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Luke A.J. O'Neill (<laoneill@tcd.ie>).

### Materials Availability {#sec4.2.2}

This study did not generate new unique reagents.

### Data and Code Availability {#sec4.2.3}

This study did not generate/analyze datasets/code.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Animal Details {#sec4.3.1}

All mice were on a C57BL/6J background unless stated below. Wild-type mice were purchased from Harlan. *Irg1* ^*−/−*^ mice (named C57BL/6N-Acod1^em1(IMPC)J^/J) were generated by CRISPR-targeted deletion of exon 4 of *Acod1*, and were purchased from The Jackson Laboratory. Wild-type littermates were used as controls. *Gsto1* ^−/−^ 129/SvEv-C57BL/6J mice were obtained from Taconic and were originally derived from 129S-5 ES cells and backcrossed to an albino C57BL/6J strain. Bones from *Nfe2l2* ^*−/−*^ mice and their wild-type counterparts were kindly provided by Professor Albena Dinkova-Kostova (University of Dundee). Bones from *Nlrp3* ^*−/−*^ mice and their wild-type counterparts were kindly provided by Professor Ed Lavelle (Trinity College Dublin). *In vivo* models were performed with 6-week old female C57BL/6J mice and littermates were randomly assigned to experimental groups. Animals were maintained under specific pathogen-free conditions in line with Irish and European Union regulations. All animal procedures were ethically approved by the Trinity College Dublin Animal Research Ethics Committee prior to experimentation, and conformed with the Directive 2010/63/EU of the European Parliament.

### Generation of Murine BMDMs {#sec4.3.2}

6-12-week old mice were euthanised in a CO~2~ chamber, and death was confirmed by cervical dislocation. Bone marrow was subsequently harvested from the tibia and fibula and cells were differentiated in DMEM containing L929 supernatant (10%), fetal calf serum (FCS) (10%), and penicillin/streptomycin (1%) for 6 days, after which cells were counted and plated at 0.5 × 10^6^ cells/mL unless otherwise stated.

### CAPS Patient Recruitment {#sec4.3.3}

Recruitment was carried out by members of the patient's own clinical team. Patients were approached to provide a voluntary blood sample for the study. Patients were provided with an information leaflet 24 h in advance of sample donation. All patients or their parents/legal guardians gave informed written consent. Direct travel costs were covered but no incentive or compensation was offered. Patient demographics were not recorded. Patients were receiving standard anti-IL-1 therapy (Anakinra). This treatment was not discontinued prior to blood sampling. The study was conducted in accordance with the Declaration of Helsinki and approved by the Joint Research Ethics Committee of St James Hospital and Tallaght Hospital (REF 2017-11) and the Ethics (Medical Research) Committee of Our Lady's Children's Hospital, Crumlin (Now Children's Health Ireland), REF: GEN/577/17.

### Isolation of Human PBMCs {#sec4.3.4}

Human blood samples from healthy donors were collected and processed at the School of Biochemistry and Immunology in TBSI (TCD). Blood samples were obtained anonymously and written informed consent for the use of blood for research purposes has been obtained from the donors. All the procedures involving experiments on human samples have been approved by the School of Biochemistry and Immunology Research Ethics Committee (TCD). Experiments were conducted according to the TCD guide on good research practice, which follows the guidelines detailed in the National Institutes of Health Belmont Report (1978) and the Declaration of Helsinki.

30 mL whole blood was layered on 20 mL Lymphoprep (Axis-Shield), followed by centrifugation for 20 min at 400 x g with the brake off, after which the upper plasma layer was removed and discarded. The layer of mononuclear cells at the plasma-density gradient medium interface was retained, and 20 mL PBS was added. Cells were centrifuged for 8 min at 300 x g and the resulting supernatant was removed and discarded. The remaining pellet of mononuclear cells was resuspended, counted and plated at 1 × 10^6^ cells/mL in RPMI supplemented with FCS (10%) and penicillin-streptomycin (1%).

### Human Monocyte Differentiation {#sec4.3.5}

Frozen human monocytes (Biological Specialty Labs) were thawed and seeded in 10 cm dishes at 1 × 10^6^ cells/mL in macrophage media (RPMI media supplemented with 10% fetal calf serum and penicillin/streptomycin) and 0.1 μg/mL recombinant human M-CSF (Peprotech) and incubated at 37°C and 5% CO2. Cells were cultured for 6 days total to differentiate the monocytes to macrophages, with removal and replacement of media and M-CSF at three days of culture.

### Culture of HEK293T Cells {#sec4.3.6}

HEK293T cells were obtained from the Centre for Applied Microbiology and Research (Wiltshire, UK) and cultured in DMEM containing FCS (10%) and penicillin-streptomycin (1%).

Method Details {#sec4.4}
--------------

### Canonical Inflammasome Assays {#sec4.4.1}

BMDMs were plated in 12-well cell culture plates and left overnight to adhere. Cells were treated the following day with LPS from *Escherichia coli*, serotype EH100 (Enzo Life Sciences, 100 ng/mL) for 3 h. Medium was removed and replaced with serum- and antibiotic-free medium and treated with compounds as required for 45 min. 4-OI, 4-O-2-MS and 4-OS were kindly supplied by Professor Richard Hartley and dissolved in DMSO. Itaconic acid (Sigma Aldrich) was dissolved at 500 mM in PBS and the required volume of NaOH was added in order to achieve a pH of 7. Cells were treated with nigericin (10 μM, Invivogen) or ATP (5 mM, Sigma Aldrich) for 45 min to activate the NLRP3 inflammasome. In order to activate the AIM2 inflammasome, LPS-primed cells were transfected with 1.5 μg poly(dA:dT) (Invivogen) using lipofectamine 2000 (Thermo Fisher Scientific) for 6 h. In order to activate the NLRC4 inflammasome, LPS-primed cells were transfected with 1.6 μg purified flagellin from *Pseudomonas aeruginosa* (Invivogen) for 2.5 h.

To activate the NLRP3 inflammasome in healthy human PBMCs, cells were treated for 14 h with LPS (200 ng/mL) or Pam3CSK4 (2 μg/mL, Invivogen). Medium was removed and replaced with serum- and antibiotic-free medium and treated with compounds as required for 45 min. Cells were subsequently treated with nigericin (6.5 μM) for 2 h. For alternative inflammasome activation in healthy human PBMCs, cells were pre-treated with compounds for 1 h, after which they were treated with LPS (200 ng/mL) for 14 h, as described previously ([@bib6]). Human CAPS PBMCs were treated for 1 h with LPS (100 ng/mL), after which medium was removed and replaced with serum- and antibiotic-free medium and treated with compounds as required for 4 h.

### Non-Canonical Inflammasome Assay {#sec4.4.2}

Cells were treated with LPS (100 ng/mL) for 3 h, after which the medium was replaced and cells were treated with compounds as required for 45 min. 2 μg LPS was transfected using FuGENE HD (Promega) overnight (18 h) in order to activate the inflammasome.

### ASC Speck Assay {#sec4.4.3}

Flow cytometry was used to analyze ASC speck formation following inflammasome activation. BMDMs were treated as desired, after which the supernatant was removed and 1 mL of cold PBS was added to the wells. Cells were then detached from the plates using a cell scraper and transferred to round-bottom tubes. 4 mL ethanol (100%) was added to the cells while simultaneously vortexing the tubes, in order to fix the cells and prevent clumping. Cells were incubated at room temperature for 15 min, before being centrifuged at 600 x g for 10 min. Supernatant was removed, and cells were resuspended in FACS buffer (0.1% Sodium azide, 0.1% BSA, 1.5% FCS in PBS) containing FC block (0.4%). Cells were incubated for 20 min at room temperature after which anti-mouse ASC antibody (Santa Cruz, sc-22514-R) was added to a final dilution of 1/1500. Cells were incubated for 90 min at room temperature. 1 mL of FACS buffer was added to the cells and they were centrifuged at 600 x g for 10 min. Supernatant was removed, and the cells were resuspended in Alexa Fluor 488 anti-rabbit IgG antibody (Invitrogen, A27304 1/1500 in FACS buffer), before being incubated in the dark for 45 min at room temperature. Cells were pelleted and resuspended in 200 μL FACS buffer. Samples were acquired on a FACSCanto (BD Biosciences). Samples were gated based on forward light scatter (FSC) versus side scatter (SSC) in order to exclude cell debris. Doublets were also excluded from analysis using FSC-area versus FSC-width analysis. Sorting was conducted by analyzing the pulse height, width and area of the 488nm laser and 530/30nm laser channel. ASC speck positive cells were detected by a decreased width or increased height in the pulse of emitted fluorescence when compared with unstimulated cells.

### ASC Oligomerisation {#sec4.4.4}

BMDMs were treated as desired. After treatment, cells were washed twice with 200 μL cold PBS before being lysed in crosslinking lysis buffer (50 mM HEPES, 0.5% Triton X-100, 1 mM phenylmethylsulfonyl fluoride (PMSF), 11.5 μg/mL aprotinin, 1 μg/mL leupeptin and 1 mM sodium orthovanadate). Samples were placed on ice for 15 min and benzonase nuclease was added in order to break down DNA in the lysates. Lysates were centrifuged for 15 min at 6000 x g at 4°C and the supernatant was removed and frozen down as the 'soluble fraction.' 20 μL of the soluble fraction was mixed with 5 μL of sample lysis buffer (0.125M Tris pH 6.8, 10% glycerol, 0.02% SDS, 5% DTT) and run on a 12% gel. The insoluble pellet was resuspended in HEPES (50 mM) and washed 3 times by centrifuging at 6000 x g at 4°C and removing the supernatant each time. After the final wash, the pellet was resuspended in 500 μL crosslinking buffer (50 mM HEPES, 150 mM NaCl) and disuccinimidyl suberate (DSS, Thermo Fisher, made up in anhydrous DMSO) was added to the final concentration of 2 mM. Immediately following the addition of DSS, the sample was inverted several times and incubated for 45 min at 37°C. The sample was then centrifuged for 15 min at 6000 x g at 4°C, before the supernatant was removed and the pellet was resuspended in 30 μL sample lysis buffer. The resuspended 'insoluble fraction' was subsequently boiled for 5 min at 95°C before being run on a gel.

### HEK293T Inflammasome Reconstitution {#sec4.4.5}

HEK293T cells were plated at a density of 2 × 10^5^ cells/mL in 24-well plates in DMEM containing FCS (10%). The following morning, cells were transfected with plasmids encoding murine GFP-IRG1 (280 ng, Origene, MG217265) and murine NLRP3 inflammasome components: HA-ASC (20 ng, Addgene, 41553), HA-NEK7 (200 ng, Addgene, 75142), FLAG-pro-caspase 1 (100 ng, Addgene, 75128), FLAG-NLRP3 (200 ng, Addgene, 75127), FLAG-Pro-IL-1β (200 ng, Addgene, 75131). Plasmids were transfected using lipofectamine 2000 for 24 h. Following the 24 h transfection, medium was replaced with DMEM containing FCS (10%) and penicillin-streptomycin (1%). 4 h later, nigericin (10 μM) was added to cells in order to activate the inflammasome. Supernatants and cell lysates were harvested 45 min later. This protocol was described previously ([@bib45]).

### Western Blotting {#sec4.4.6}

Supernatant was removed from cells following stimulation and lysates were harvested in 30-50 μL lysis buffer (0.125 M Tris pH 6.8, 10% glycerol, 0.02% SDS, 5% DTT) Lysates were subsequently heated to 95°C for 5 min to denature proteins. In order to concentrate supernatants for western blot, 5 μL Strataclean Resin (Agilent) was added to 500 μL of supernatant and vortexed for 1 min. Supernatants were then centrifuged at 210 x g for 2 min at 4°C. Supernatants were removed and discarded, and the remaining pellet was resuspended in 30 μL lysis buffer. SDS-PAGE was used to resolve proteins by molecular weight. Samples were boiled at 95°C for 5 min prior to loading into a 5% stacking gel. The percentage resolving gel depended on the molecular weight of the given protein. The Bio-Rad gel running system was used to resolve proteins and the Bio-Rad wet transfer system was used for the electrophoretic transfer of proteins onto PVDF membrane. Following transfer, the membrane was incubated in milk powder (5% in TBST) for 1 h and subsequently incubated in primary antibody rolling overnight at 4°C. The membrane was incubated for 1 h with secondary antibody (diluted in 5% milk powder) at room temperature. Prior to visualization, the membrane was immersed in WesternBright ECL Spray (Advansta). Protein visualization took place on a ChemiDoc MPTM Imaging System (Bio-Rad), and both chemiluminescent and white light images were taken. Quantification of western blot images was performed using Image Lab Software (Bio-Rad). Adjusted band volume was calculated for each band and for each experimental condition this was presented as target protein/housekeeping protein.

### Co-Immunoprecipitation {#sec4.4.7}

BMDMs were seeded at 1x10^6^ cells/mL in 10 cm dishes the day prior to treatment. The following day, cells were treated as required. Following treatment, cells were washed with 3 mL PBS before lysis in 500 μL low stringency lysis buffer (50 mM HEPES pH 7.5, 100 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% Nonident P40 (NP-40), 1 mM phenylmethylsulfonyl fluoride (PMSF), 11.5 μg/mL aprotinin, 1 μg/mL leupeptin and 1 mM sodium orthovanadate) on ice. Plates were scraped with a cell scraper and lysate transferred into microcentrifuge tubes. Tubes were agitated at 1100 rpm at 4°C for 15 min before being centrifuged at 21380 x g for 10 min at 4°C. 25 μL of resulting supernatant was mixed with 25 μL sample lysis buffer and treated as the whole cell lysate (WCL) sample. 0.0153 mg/mL anti-NEK7 antibody (Abcam, ab133514) or the equivalent concentration of rabbit IgG antibody (Millipore, pp64), and 40 μL A/G PLUS agarose beads (Santa Cruz) was added to the remaining supernatant, which was subsequently incubated at 4°C in a ferris wheel mixer for 3 h. IP samples were subsequently centrifuged at 400 x g for 2 min at 4°C, supernatant removed, and beads washed three times with 1 mL low stringency lysis buffer. The immune complexes were eluted by addition of 40 μL sample lysis buffer, boiled for 5 min and analyzed by SDS-PAGE.

### ELISA {#sec4.4.8}

DuoSet ELISA kits for IL-1β, TNFα and IL-6 were purchased from R&D Systems and were carried out according to the manufacturer's instructions with appropriately diluted cell supernatants added to each plate in duplicate or triplicate. Quantikine ELISA kits for IL-1β (R&D Systems) and IL-18 (Invitrogen) were similarly carried out according to the manufacturer's instructions. Absorbance at 450 nm was then quantified using a FLUOstar Optima plate reader. Corrected absorbance values were calculated by subtracting the background absorbance, and cytokine concentrations were subsequently obtained by extrapolation from a standard curve plotted on GraphPad Prism 8.0.

### LDH Assay {#sec4.4.9}

The CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega) was used to quantify lactate dehydrogenase (LDH) release from cells as a measure of cell death in BMDMs following inflammasome stimulation. Freshly harvested supernatants were used in this assay. 50 μL of each supernatant was added to 50 μL Cytotox 96 Reagent and incubated in the dark at room temperature for 30 min. 50 μL acetic acid was added to stop the reaction, and the absorbance at 492 nm was measured using a FLUOstar optima. 100 μL total lysis solution was added to untreated cells 30 min before harvesting and served as a maximum LDH release control. Medium alone was also used to correct for background absorbance.

### Generation of ^13^C~5~ Octyl Itaconate {#sec4.4.10}

All NMR spectra were collected using a Varian 400 MHz NMR. Synthesis was performed by WuXi AppTec. Synthesis of ^13^C~5~ octyl itaconate was performed as previously described ([@bib40]) with minor modifications. Uniformly labeled ^13^C~6~-citric acid (0.32 mmol) was placed into a distillation apparatus and subjected to pyrolysis by heating to 175°C for 30 min with constant stirring. The reaction was then heated up to 200°C at a pressure of 2 Torr. Heating was maintained for 2 h. The cyclised product was collected as a white solid in the distillation bulb at a temperature of −20°C (3.9% yield). Equimolar quantities of the product and octanol (20 mM final concentration) were mixed in toluene, heated to 100°C and stirred for 12 h. The mixture was concentrated and subjected to preparative HPLC using a Shimadzu LC-8A preparative HPLC with a Waters Xbridge column (150 mm x 25 mm, 5 μM). Mobile phase consisted of 10 mM ammonium bicarbonate in water with a gradient of acetonitrile from 15% to 45% over 20 min with a flow rate of 30 mL/min. Purified yield of ^13^C~5~-octylitaconate was 20%. Synthesis of ^13^C~5~-octylitaconate was confirmed by ^1^H NMR and LC/MS (ESI+).

### Treatment of Human Macrophages with ^13^C~5~ Octyl Itaconate {#sec4.4.11}

At the end of the macrophage differentiation, medium was removed and replaced with macrophage medium with or without 100 ng/mL of LPS, from *Escherichia coli* serotype O127:B8 (Sigma) and 125 μM ^13^C~5~ octyl itaconate dissolved in DMSO and incubated for various times at 37°C and 5% CO2. In cultures with ^13^C~5~ octyl itaconate alone, supernatants and cells were harvested 0.5, 3, 6, 9 and 27 h after addition of ^13^C~5~ octyl itaconate. Cultures with LPS were treated with ^13^C~5~ octyl itaconate three h prior or three h following LPS addition. Supernatants and cells were harvested 3, 6 and 24 h post LPS if added after ^13^C~5~ octyl itaconate and 6, 9 and 24 h post LPS if added before ^13^C~5~ octyl itaconate. Control cultures without ^13^C~5~ octyl itaconate included cells alone and 24 h treatment with LPS. Supernatants were transferred to Eppendorf tubes and stored at −80°C until analysis. Cells were washed with D-PBS (GIBCO), trypsinized (GIBCO), scraped with a cell scraper and transferred to conical tubes. Cells were washed three times with 40 mM ammonium formate (Sigma) and transferred to Eppendorf tubes prior to snap freezing on dry ice and stored at −80°C until analysis.

### Measurement of ^13^C~5~ Itaconate and ^13^C~5~ Octyl Itaconate in Human Macrophages by LC-HRMS {#sec4.4.12}

Cell pellet samples were thawed on wet ice immediately prior to analysis. 1 mL of ice cold 8:2 methanol-water (Sigma; Milli-Q water) was added to each sample. The tubes were briefly vortexed, sonicated (10 min/ice bath), and briefly vortexed again to lyse cells and extract analytes. Each sample was centrifuged at 6°C for 15 min at 15,000 x g. 450 μL of supernatant was transferred to a 1.5 mL glass autosampler vial, dried down, and derivatized with 3-nitrophenylhydrazine (3-NPH) (Sigma) using a modification of method previously reported method ([@bib10]). 100 μL of a 250 mM 3-NPH solution (1:1 acetonitrile-water) and 200 μL of a 143.5 mM EDC.HCl solution (1:1 water:acetonitrile containing 6%(v/v) pyridine) were added to each vial. The samples were briefly vortexed and left at room temperature for 2 h. After adding 500 μL chloroform (Sigma) and 100μL of cold 3N HCl (VWR) each vial was vortexed for about 5 s, and the layers were allowed to separate. 450 μL of the lower organic layer was transferred to a Microsolv Max Recovery 1.2 mL glass vial and dried down. The residue was reconstituted in 100 μL of methanol-water (1:1) for analysis by LC-HRMS.

The LC-HRMS system consisted of an Agilent 1290 HPLC system coupled to an Agilent 6550 Q-TOF mass spectrometer equipped with a Jet Stream ESI source. The chromatographic analysis was performed with a Waters Acquity BEH C18 column (100 × 2.1 mm, 1.7 μm) maintained at 35°C and an elution gradient composed of water (A) and acetonitrile (B). The gradient elution profile was 0.5% B for 2 min, 90% B at 20 min, 90% B to 28 min with column re-equilibration at 0.5% B from 28.05 to 33 min. The flow rate was 0.35 mL/min and the injection volume was 3 μL. The mass spectrometer was operated in negative ion mode with the following source settings: Gas Temp: 290°C, Drying Gas: 12 L/min, Nebulizer: 55 psi, Sheath Gas Temp: 400°C, Sheath Gas Flow: 12, Vcap: 3000V, Nozzle: 1000V. Acquisition rate: 1.5 spectra/s.

### Analysis of NLRP3 Modification by 4-OI {#sec4.4.13}

HEK293T cells were plated at a density of 3 × 10^5^ cells/mL in 10 cm dishes in DMEM containing FCS (10%). The following morning, cells were transfected with 5 μg of plasmid encoding murine FLAG-NLRP3 (Addgene, 75127) using lipofectamine 2000. 24 h after transfection, cells were treated with 4-OI (250 μM) or vehicle control (DMSO) for a further 24 h. Following treatment, cells were washed with 3 mL PBS before lysis in 500 μL low stringency lysis buffer (50 mM HEPES pH 7.5, 100 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% Nonident P40 (NP-40), 1 mM phenylmethylsulfonyl fluoride (PMSF), 11.5 μg/mL aprotinin, 1 μg/mL leupeptin and 1 mM sodium orthovanadate) on ice. Plates were scraped with a cell scraper and lysate transferred into microcentrifuge tubes. Tubes were agitated at 1100 rpm at 4°C for 15 min before being centrifuged at 21380 x g for 10 min at 4°C. FLAG-tagged NLRP3 was immunoprecipitated using an anti-FLAG antibody (1 mg/mL, Sigma, F1804) and 70 μL A/G PLUS agarose beads (Santa Cruz), placed in a ferris wheel mixer at 4°C for 3 h. IP samples were subsequently centrifuged at 400 x g for 2 min at 4°C, supernatant removed, and beads washed three times with 1 mL low stringency lysis buffer. The immune complexes were eluted by addition of 40 μL sample lysis buffer, boiled for 5 min and run on a 8% gel. The resulting gel was subsequently fixed in Coomassie fixing solution (50% methanol, 10% acetic acid in ddH~2~O) for 30 min, followed by removal of the fixing solution and incubation in Coomassie blue R-250 buffer (0.125 g Coomassie Blue R-250 (Cayman Chemical), 5 mL acetic acid, 22.5 mL methanol, 22.5 mL ddH~2~O) for 1 h. Staining solution was then removed from the gel, which was washed repeatedly with de-staining solution (5% methanol, 7.5% acetic acid in ddH~2~O). The corresponding bands for FLAG-NLRP3 were excised from the gel and subjected to in-gel digest with elastase (Promega). In brief, the gel slices were cut into smaller pieces (1--2 mm^3^) before reduction with DTT (10 mM) and alkylation with iodoacetamide (50 mM). Gel slices were digested with elastase (1 μg) overnight at 37 °C. Following protease digest, peptides were eluted from the gel pieces and dried down completely in a vacuum centrifuge. Samples were analyzed in an Orbitrap Fusion Lumos coupled to a UPLC ultimate 3000 RSLCnano System (both Thermo Fisher). MS data was analyzed with PEAKS Studio 8 (Bioinformatics Solutions). Precursor mass tolerance was set to 10 ppm, while fragments were detected with a tolerance of 0.5 Da. Oxidation (M), Deamidation (N, Q), Carbamidomethylation (C), dicarboxypropylation of cysteine by 4-OI (C) (+242.15 Da) were defined as variable modifications. Peptide FDR was set to 1%.

### MSU-Induced Peritonitis Model {#sec4.4.14}

6-week old female C57BL/6J mice were injected intraperitoneally with a mixture of 4-OI (50 mg/kg) in 60% cyclodextrin in PBS and MSU crystals (30mg/kg, Invivogen) suspended in PBS for 6 h. Mice were euthanized in a CO~2~ chamber and peritoneal lavage was performed using 2.5 mL PBS. The cells in the lavage fluid were pelleted and the supernatant was removed and analyzed by ELISA for IL-1β and IL-6 concentration. Cells were resuspended in 1 mL PBS and passed through a 70 μm filter. 100 μL cells was removed for FACS analysis and the remaining cells were counted using a TC20™ automated cell counter (Biorad) with a minimum size gate of 8 μm and a maximum gate of 20 μm. 100 μL cells were incubated for 20 min at RT with Zombie Green (Biolegend, 1/800). Cells were then washed and incubated for 10 min at RT with anti-mouse CD16/CD32 (BD Biosciences) in 100 μL PBS. After 10 min, 1 μg of the following antibodies was added: APC/Cy7 anti-mouse CD45 (Biolegend), eFluor660 anti-mouse CD11b (ThermoFisher Scientific) and Pacific Blue anti-mouse Ly6G (Biolegend). After 20 min, cells were washed, resuspended in PBS and analyzed on a FACS Canto II Cell Analyzer (BD Biosciences). Neutrophils were identified as Zombie Green negative (live cells), CD45^+^CD11b^+^Ly6G^+^ cells. Analysis of acquired data was performed with the FlowJo software (FlowJo LLC). The total number of neutrophils obtained from each mouse was calculated by multiplying the percentage neutrophils with the total cell count obtained.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Details of all statistical analyses performed can be found in the figure legends. Data were expressed as mean ± standard error of the mean (SEM) and p values were calculated using two-tailed Student's t test for pairwise comparison of variables and one-way ANOVA for multiple comparison of variables. A Sidak's multiple comparisons test was used as a post-test when performing an ANOVA. A confidence interval of 95% was used for all statistical tests. Statistical tests were not performed on western blot quantification figures due to the semiquantitative nature of these data. Significance was defined as follows: ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. Sample sizes were determined on the basis of previous experiments using similar methodologies. All depicted data points are biological replicates taken from distinct samples. Each figure consists of a minimum of 3 independent experiments from multiple biological replicates. n = the number of animals or the number of independent experiments with cell lines. For *in vivo* studies, mice were randomly assigned to treatment groups. For mass spectrometry analyses, samples were processed in random order and experimenters were blinded to experimental conditions.
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